Core Viewpoint - The project led by the company for the development of a novel inhaled nucleic acid drug has been selected as a major technological project in Jiangsu Province for 2025, focusing on innovative biopharmaceuticals [1] Group 1: Project Overview - The project addresses key challenges in the pulmonary delivery of small nucleic acid (siRNA) drugs and aims to advance the translational research and preclinical development of inhaled nucleic acid candidates [1] - The project plans to support the research and development of inhaled nucleic acid candidates targeting major respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis [1] Group 2: Strategic Importance - The selection of this project is considered strategically significant for the company, further validating the strength of its technological platform [1] - Delivery technology is identified as a critical barrier for siRNA treatments in the lungs, and the company has developed an efficient lung-targeted delivery system [1] Group 3: Research and Development - The project encompasses the optimization of delivery systems, formulation and process development, preclinical research, and preparation for new drug clinical trial applications [1] - The candidates developed under this project have shown promising therapeutic potential in preclinical studies [1] - The recognition from relevant departments and expert reviewers highlights the company's collaborative research capabilities in advanced delivery technology [1]
长风药业(02652.HK)：主导项目入选2025年江苏省科技重大专项“创新生物药”项目